Skip to main content

Table 3 Proportion of patients with prolonged PT-INR at peak daptomycin concentration and the relative change of PT-INR between trough and peak

From: Dose-dependent artificial prolongation of prothrombin time by interaction between daptomycin and test reagents in patients receiving warfarin: a prospective in vivo clinical study

Reagent PT-INRpeak > PT-INRtrough (%) p valuea PT-INRpeak/PT-INRtrough (95% CI) p valueb
1 26/35 (74%) 0.006 1.05 (1.02–1.07) 1.00
2 27/35 (77%) 0.002 1.04 (1.01–1.07) 1.00
3 31/35 (89%) <0.001 1.07 (1.03–1.11) 0.94
4 20/35 (57%) 0.50 1.00 (0.98–1.02) 1.00
5 20/35 (57%) 0.50 1.01 (0.98–1.03) 1.00
6 20/35 (57%) 0.50 1.02 (0.97–1.07) 1.00
7 25/35 (71%) 0.02 1.04 (1.01–1.08) 1.00
8 25/35 (71%) 0.02 1.05 (1.01–1.09) 0.99
9 19/35 (54%) 0.74 1.00 (0.98–1.02) 1.00
  1. PT-INR prothrombin time-international normalised ratio, CI confidence interval
  2. ap values by binomial test compared to 0.50
  3. bOne-sided p value by t test to test whether the ratio is more than 1.10